Pyxis (PYXS) Return on Sales by Net Profit

Brandmark of Pyxis Oncology Inc. (PYXS)

Pyxis Oncology, Inc. (PYXS) maintains a speculative business moat based on its immuno-oncology patent portfolio. The management's high scientific expertise ensures transparency in the development of ADC drugs. The company's net margin ratio demonstrates adaptability to interest rates, while -785.50 reflects the latest value of the metric. Innovative treatment methods and proprietary antibodies build capital that will be monetized through future sales.

PYXS: pyxisoncology.com Company Net Profitability 07/04/2022 - 11/20/2026

Analytical breakdowns for Pyxis Oncology, Inc.

- market value and analyst target forecast:
Summary company analytics:Pyxis - PYXS
Flagship merchandise of pyxisoncology.com

This metric is calculated as the ratio of net income to total revenue, determining the portion of capital remaining with the business after deducting all operating and tax expenses. Negative net profit margin values for Pyxis Oncology, Inc. (PYXS) are driven by colossal expenditures on clinical trials and R&D, which is typical for the high-tech cancer immunotherapy sector.